Diferencia entre revisiones de «Tranexamic acid»
(→Source) |
|||
| Línea 29: | Línea 29: | ||
==See Also== | ==See Also== | ||
*[[EBQ:MATTERs_Study|MATTERs Study]] | |||
*[[EBQ:CRASH-2_Trial|Crash-2 Trial]] | |||
*[[Transfusions]] | *[[Transfusions]] | ||
*[[Transfusion Reactions]] | *[[Transfusion Reactions]] | ||
Revisión del 01:18 15 jul 2014
Background
- Action: Antifibrinolytic agent
- Availability:
- Ampule of 1 Gm in 10 mL
Indication
Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min., with expected requirement for massive transfusion.
Contraindication/Exclusion Criteria
- Greater than 3 hours from injury
- Known sensitivity to TXA
- Previous DVT or Pulmonary Embolism
Administration
- Adult dose- Total of 2 Gms
- Initial bolus of 1 Gm over 10 minutes (Slow IV push). Draw up with filter needle.
- Maintenance: additional 1 Gm over next 8 hours (mix in 50 mL of NS). Call Pharmacy to mix and deliver the continuous infusion.
- Pediatric dose- (weight based)
- Initial bolus of 20 mg/kg IV Bolus over 10 minutes
- Maintenance: 10 mL/kg/hr over next 8 hours
No additional laboratory tests required.
Adverse Reactions
- Thrombotic events
- Hypotension with rapid injection
- Nausea, vomiting, diarrhea
- Impaired color vision and other visual disturbances
See Also
Source
Harbor-UCLA Tranexamic Acid (TXA) Guidelines for Administration in Trauma